Tim Anderson
Stock Analyst at B of A Securities
(2.47)
# 2,225
Out of 4,748 analysts
21
Total ratings
70%
Success rate
7.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $159 | $151.15 | +5.19% | 3 | Jan 23, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $26.62 | +8.94% | 1 | Dec 10, 2024 | |
| BMY Bristol-Myers Squibb Company | Reinstates: Neutral | $63 | $59.05 | +6.69% | 1 | Dec 10, 2024 | |
| BIIB Biogen | Reinstates: Neutral | $178 | $144.41 | +23.26% | 1 | Dec 10, 2024 | |
| ABBV AbbVie | Reinstates: Neutral | $191 | $175.26 | +8.98% | 4 | Dec 10, 2024 | |
| REGN Regeneron Pharmaceuticals | Reinstates: Underperform | $565 | $687.27 | -17.79% | 1 | Dec 10, 2024 | |
| MRNA Moderna | Reinstates: Underperform | $41 | $40.72 | +0.69% | 1 | Dec 10, 2024 | |
| AMGN Amgen | Reinstates: Underperform | $256 | $281.68 | -9.12% | 2 | Dec 10, 2024 | |
| MRK Merck & Co. | Reinstates: Buy | $121 | $98.28 | +23.12% | 3 | Dec 10, 2024 | |
| GILD Gilead Sciences | Reinstates: Buy | $109 | $95.59 | +14.03% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $804.08 | +23.99% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $102.93 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.25 | - | 1 | Sep 22, 2017 |
Johnson & Johnson
Jan 23, 2025
Maintains: Neutral
Price Target: $160 → $159
Current: $151.15
Upside: +5.19%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $26.62
Upside: +8.94%
Bristol-Myers Squibb Company
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $59.05
Upside: +6.69%
Biogen
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $144.41
Upside: +23.26%
AbbVie
Dec 10, 2024
Reinstates: Neutral
Price Target: $191
Current: $175.26
Upside: +8.98%
Regeneron Pharmaceuticals
Dec 10, 2024
Reinstates: Underperform
Price Target: $565
Current: $687.27
Upside: -17.79%
Moderna
Dec 10, 2024
Reinstates: Underperform
Price Target: $41
Current: $40.72
Upside: +0.69%
Amgen
Dec 10, 2024
Reinstates: Underperform
Price Target: $256
Current: $281.68
Upside: -9.12%
Merck & Co.
Dec 10, 2024
Reinstates: Buy
Price Target: $121
Current: $98.28
Upside: +23.12%
Gilead Sciences
Dec 10, 2024
Reinstates: Buy
Price Target: $109
Current: $95.59
Upside: +14.03%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $804.08
Upside: +23.99%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $102.93
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $70.25
Upside: -